Guangzhou Kingmed Diagnostics Group Co., Ltd. (SHA:603882)
China · Delayed Price · Currency is CNY 27.31
-0.89 (-3.16%)
Apr 28, 2026, 3:00 PM CST
SHA:603882 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 5,915 | 6,030 | 6,627 | 7,726 | 14,529 | 11,304 |
Other Revenue | - | - | 562.98 | 813.43 | 946.76 | 639.52 |
| 5,915 | 6,030 | 7,190 | 8,540 | 15,476 | 11,943 | |
Revenue Growth (YoY) | -13.21% | -16.12% | -15.81% | -44.82% | 29.58% | 44.88% |
Cost of Revenue | 3,836 | 3,935 | 4,807 | 5,425 | 8,802 | 6,295 |
Gross Profit | 2,079 | 2,095 | 2,383 | 3,115 | 6,674 | 5,648 |
Selling, General & Admin | 1,507 | 1,527 | 1,529 | 1,730 | 2,506 | 2,323 |
Research & Development | 338.46 | 341.28 | 400.47 | 467.14 | 632.62 | 517.93 |
Other Operating Expenses | -7.51 | -16 | 15.91 | 14.91 | 14.75 | 11.71 |
Operating Expenses | 1,838 | 1,853 | 2,564 | 2,700 | 3,409 | 2,924 |
Operating Income | 240.86 | 242.3 | -180.92 | 414.93 | 3,266 | 2,724 |
Interest Expense | - | - | -18.43 | -20.39 | -23.65 | -27.55 |
Interest & Investment Income | 3.2 | 3.84 | 23.48 | 288.36 | 30.4 | 21.53 |
Earnings From Equity Investments | 1.52 | - | - | - | - | - |
Currency Exchange Gain (Loss) | - | - | 0.2 | -0.6 | 9.14 | -1.46 |
Other Non Operating Income (Expenses) | -309.86 | -418.47 | -2.7 | -2.95 | -3.91 | -2.54 |
EBT Excluding Unusual Items | -64.28 | -172.33 | -178.37 | 679.35 | 3,278 | 2,714 |
Gain (Loss) on Sale of Investments | -10 | -2.12 | -140.82 | - | -10.8 | -7.29 |
Gain (Loss) on Sale of Assets | 2.69 | 4.4 | -143.59 | -7.57 | 2.97 | -10.11 |
Asset Writedown | -11.63 | -11.55 | - | - | - | - |
Other Unusual Items | - | - | 24.14 | 68.51 | 50.64 | 50.87 |
Pretax Income | -83.22 | -181.61 | -438.65 | 740.29 | 3,321 | 2,748 |
Income Tax Expense | 12.77 | -3.01 | -23.94 | 103.38 | 475.72 | 384.05 |
Earnings From Continuing Operations | -95.99 | -178.6 | -414.7 | 636.91 | 2,845 | 2,364 |
Minority Interest in Earnings | -6.68 | 5.36 | 33.46 | 6.47 | -90.22 | -143.87 |
Net Income | -102.67 | -173.24 | -381.24 | 643.38 | 2,755 | 2,220 |
Net Income to Common | -102.67 | -173.24 | -381.24 | 643.38 | 2,755 | 2,220 |
Net Income Growth | - | - | - | -76.64% | 24.11% | 47.02% |
Shares Outstanding (Basic) | 471 | 468 | 465 | 466 | 466 | 462 |
Shares Outstanding (Diluted) | 471 | 468 | 465 | 466 | 467 | 466 |
Shares Change (YoY) | 1.53% | 0.71% | -0.28% | -0.15% | 0.13% | 1.00% |
EPS (Basic) | -0.22 | -0.37 | -0.82 | 1.38 | 5.91 | 4.80 |
EPS (Diluted) | -0.22 | -0.37 | -0.82 | 1.38 | 5.90 | 4.76 |
EPS Growth | - | - | - | -76.61% | 23.95% | 45.57% |
Free Cash Flow | 765.7 | 778.55 | 459.99 | 516.07 | 1,107 | 1,136 |
Free Cash Flow Per Share | 1.63 | 1.66 | 0.99 | 1.11 | 2.37 | 2.44 |
Dividend Per Share | - | - | 0.880 | 0.880 | 1.780 | 1.280 |
Dividend Growth | - | - | - | -50.56% | 39.06% | 289.06% |
Gross Margin | 35.15% | 34.74% | 33.15% | 36.48% | 43.13% | 47.29% |
Operating Margin | 4.07% | 4.02% | -2.52% | 4.86% | 21.10% | 22.81% |
Profit Margin | -1.74% | -2.87% | -5.30% | 7.53% | 17.80% | 18.58% |
Free Cash Flow Margin | 12.95% | 12.91% | 6.40% | 6.04% | 7.16% | 9.51% |
EBITDA | 539.97 | 569.34 | 257.86 | 866.66 | 3,679 | 3,056 |
EBITDA Margin | 9.13% | 9.44% | 3.59% | 10.15% | 23.77% | 25.59% |
D&A For EBITDA | 299.1 | 327.04 | 438.78 | 451.73 | 412.85 | 331.56 |
EBIT | 240.86 | 242.3 | -180.92 | 414.93 | 3,266 | 2,724 |
EBIT Margin | 4.07% | 4.02% | -2.52% | 4.86% | 21.10% | 22.81% |
Effective Tax Rate | - | - | - | 13.96% | 14.33% | 13.98% |
Revenue as Reported | - | - | 7,190 | 8,540 | 15,476 | 11,943 |
Advertising Expenses | - | - | 0.76 | 2.16 | 3.29 | 3.16 |
Updated Mar 31, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.